Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:info@kmdbioscience.com
Catalog Number | YR1248 |
---|---|
Product Name | Anti-Human APP Abeta40 Recombinant Antibody |
Molecular Name | Ponezumab |
Alias | Anti-APP Abeta40 Recombinant Antibody, Research Grade Ponezumab |
CAS Number | 1178862-65-1 |
Target | APP Abeta40[Homo sapiens] |
Isotype | IgG2 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Applications | ELISA, IP, FCM, FuncS, Neut |
Buffer | PBS, pH7.5 |
Background | Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial. Detailed reports have to be released. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |